TGFB1 and diabetic kidney disease: Clinical trials in diabetic nephropathy, septic acute kidney injury and focal segmental glomerulosclerosis have examined the direct targeting of TGF-β1 with disappointing results, highlighting the diversity and complexity of TGF-β1 signalling in renal fibrosis and inflammation.